Table I.
Factors |
Sox2 gene status
|
p-value | ||
---|---|---|---|---|
Amplified Patients (n=42) | Normal Patients (n=85) | |||
Mean age (years) | 66.0±10.2 | 67.1±8.7 | 65.5±10.8 | 0.4134 |
Stage | ||||
I | 26 (61.9%) | 52 (61.2%) | 0.9999 | |
II–IV | 16 (38.1%) | 33 (38.8%) | ||
Lymph node metastasis | ||||
N0 | 29 (55.8%) | 56 (65.9%) | 0.2779 | |
N(+) | 23 (44.2%) | 29 (34.1%) | ||
Smoking status | ||||
Never smoker | 2 (4.8%) | 28 (32.9%) | 0.0003 | |
Smoker | 40 (95.2%) | 57 (67.1%) | ||
Differentiation | ||||
Well-differentiated | 6 (15.4%) | 21 (31.3%) | 0.1046 | |
Moderate/poor | 33 (64.6%) | 46 (68.7%) | ||
Pathological subtype | ||||
Squamous | 39 (92.9%) | 48 (56.5%) | ||
Non-squamous | 3 (7.1%) | 37 (43.5%) | <0.0001 | |
Age | ||||
≤65 | 18 (42.9%) | 39 (45.9%) | 0.8501 | |
>65 | 24 (57.1%) | 46 (54.1%) | ||
Gender | ||||
Male | 38 (90.5%) | 56 (65.9%) | 0.0026 | |
Female | 4 (9.5%) | 29 (34.1%) |
N0, lymph node metastasis negative; N(+), lymph node metastasis positive; Squamous, squamous cell carcinoma.